Fentanyl
NDC Package 61919-603-05
Package Information
Fentanyl is transdermal system is indicated for the management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long- term opioid treatment and for which alternative treatment options are inadequate.Patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid.Limitations of UseBecause of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve fentanyl transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Marketed by Directrx, this product is identified by NDC 61919-603 and is authorized under FDA application ANDA077449.
Identification & Billing
- RxCUI: 245135 - fentaNYL 50 MCG/HR 72HR Transdermal System
- RxCUI: 245135 - 72 HR fentanyl 0.05 MG/HR Transdermal System
- RxCUI: 245135 - fentanyl 50 MCG/HR 3 Day Transdermal Patch
- RxCUI: 245135 - fentanyl 50 MCG/HR 72HR Transdermal System
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 61919 - Directrx
- 61919-603 - Fentanyl
- 61919-603-05 - 72 h in 1 PATCH
- 61919-603 - Fentanyl
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 61919-603-05 identifies a specific commercial package of 72 h in 1 patch of Fentanyl, labeled by Directrx. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Directrx on January 01, 2015. The current certification is valid through December 31, 2022.
How is this Directrx product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 61919060305. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.